Women's attitude towards prenatal screening for red blood cell antibodies, other than RhD

por Koelewijn, JM, Vrijkotte, TGM, de Haas, M, van der Schoot, CE, Bonsel, GJ
Publicado 2008

Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis

por Koelewijn, JM, de Haas, M, Vrijkotte, TGM, van der Schoot, CE, Bonsel, GJ
Publicado 2009

Interference of PR3-ANCA with the enzymatic activity of PR3

por Rarok, AA, van der Geld, YM, Tool, ATJ, de Haas, M, Limburg, PC, Kallenberg, CGM, Roos, D
Publicado 2002

Persistent Inflammation in Pulmonary Granuloma 48 Years after Talcage Pleurodesis, Detected by FDG-PET/CT

por Fanggiday, J. C., Rouse, R. W., Collard, S. M., de Haas, M. J., de Klerk, J. M. H.
Publicado 2012

Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures

por Zwiers, C., Lindenburg, I. T. M., Klumper, F. J., de Haas, M., Oepkes, D., Van Kamp, I. L.
Publicado 2017

Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study

por Slootweg, Y. M., Zwiers, C., Koelewijn, J. M., van der Schoot, E., Oepkes, D., van Kamp, I. L., de Haas, M.
Publicado 2022

Halting targeted and collateral damage to red blood cells by the complement system

por Jalink, M., de Boer, E. C. W., Evers, D., Havinga, M. Q., Vos, J. M. I., Zeerleder, S., de Haas, M., Jongerius, I.
Publicado 2021

Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.

por Eijdems, E. W., Zaman, G. J., de Haas, M., Versantvoort, C. H., Flens, M. J., Scheper, R. J., Kamst, E., Borst, P., Baas, F.
Publicado 1995

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.

por Eijdems, E. W., de Haas, M., Timmerman, A. J., Van der Schans, G. P., Kamst, E., de Nooij, J., Astaldi Ricotti, G. C., Borst, P., Baas, F.
Publicado 1995

P1530: PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.

por de Boer, E. C. W., Jalink, M., Delvasto-Nuñes, L., Meulenbroek, E. M., Baas, I., Janssen, S. R., Dijkman, E. E., Gelderman, K. A., Wouters, D., Engel, M. D., de Haas, M., Kersten, M.-J., Jongerius, I., Zeerleder, S., Vos, J. M.
Publicado 2022